Prabhat Sandhya Manthan Samiksha Anveshan Archive

PrabhatDawn SandhyaDusk ManthanChurning SamikshaReview AnveshanInvestigation Archive Companies About Sign in

Sign in Subscribe

Institutional-quality research on Indian markets — before the opening bell, after the close, and in depth. Led by Dr. Murali Kalyanaraman, global CFO for 30+ years.

Research

Market Prabhat · Morning Market Sandhya · Evening Market Manthan · Weekly Samiksha · Results Anveshan · Deep dives

Explore

The archive Companies Search RSS feed

Oorjita

About & method Membership Disclaimer Privacy Terms

Oorjita.AI publishes research and commentary for information and education only. Nothing on this site is investment advice or a recommendation to buy or sell any security.Oorjita Financial Services LLP is not a SEBI-registered investment adviser or research analyst; please consult a SEBI-registered professional before investing. Market data may be delayed or provisional.
Grievance Officer: Murali Kalyanaraman · services@oorjita.ai · +91 93531 73147 · Room 202, 2nd Floor, No. 164, 11th Cross, Paduka Mandira Road, BHCS Layout 4th Stage, Uttarahalli Hobli, Bengaluru 560061, Karnataka, India

Researched & written in IndiaPrices in rupeesTimes in ISTNSE · BSE · Nifty 50 · Sensex

© 2026 Oorjita Financial Services LLP · Oorjita.AI · Investing Beyond Today.

NSE: ALIVUS · Pharma

Alivus Life Sciences

1 Oorjita research notes discuss Alivus Life Sciences.

Oorjita AnveshanSun, 2 Nov, 2025

Alivus Life Sciences: Margins Expand Even After Losing PLI Benefits

Strong YoY growth in revenue and profitability, margin expansion, and operational efficiency despite loss of PLI benefits.

Alivus Life Sciences (NSE: ALIVUS) — analysis & research · Oorjita.AI